Baker BROS. Advisors LP Cuts Stake in Compass Therapeutics, Inc. $CMPX

Key Points

• Baker BROS. Advisors LP decreased its stake in Compass Therapeutics by 64.9%, now holding 547,498 shares valued at approximately $1,040,000.
• Several institutional investors, including Wells Fargo & Company and Renaissance Technologies LLC, increased their positions in Compass Therapeutics during the fourth quarter.
• Analysts have rated Compass Therapeutics with an average of "Buy" and set a consensus price target of $12.89, with individual price objectives up to $32.00.

Baker BROS. Advisors LP cut its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 64.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 547,498 shares of the company's stock after selling 1,010,132 shares during the period. Baker BROS. Advisors LP owned approximately 0.40% of Compass Therapeutics worth $1,040,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of CMPX. Wells Fargo & Company MN boosted its position in shares of Compass Therapeutics by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 59,860 shares of the company's stock valued at $87,000 after buying an additional 13,038 shares during the last quarter. Invesco Ltd. boosted its position in shares of Compass Therapeutics by 11.3% during the fourth quarter. Invesco Ltd. now owns 39,483 shares of the company's stock valued at $57,000 after buying an additional 4,018 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Compass Therapeutics by 25.2% during the fourth quarter. Renaissance Technologies LLC now owns 278,600 shares of the company's stock valued at $404,000 after buying an additional 56,000 shares during the last quarter. Barclays PLC boosted its position in shares of Compass Therapeutics by 13.2% during the fourth quarter. Barclays PLC now owns 192,766 shares of the company's stock valued at $279,000 after buying an additional 22,521 shares during the last quarter. Finally, Mariner LLC purchased a new stake in shares of Compass Therapeutics during the fourth quarter valued at $30,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CMPX has been the topic of several recent analyst reports. Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 price objective on the stock in a research report on Tuesday, July 1st. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, August 12th. Finally, Guggenheim increased their price objective on Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $12.89.

Compass Therapeutics Stock Performance

NASDAQ:CMPX opened at $3.49 on Tuesday. Compass Therapeutics, Inc. has a 12-month low of $1.25 and a 12-month high of $4.08. The stock has a 50-day moving average price of $2.95 and a 200 day moving average price of $2.47. The stock has a market capitalization of $482.60 million, a P/E ratio of -7.76 and a beta of 1.50.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). On average, research analysts predict that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.